A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Emibetuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Dec 2017 Primary endpoint (Progression Free Survival (PFS) Rate) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
- 01 Dec 2017 Results assessing activity, safety and pharmacokinetics of emibetuzumab published in the Cancer Chemotherapy and Pharmacology
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015